Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
暂无分享,去创建一个
[1] L. Moreland,et al. A review of biosimilars for rheumatoid arthritis. , 2022, Current opinion in pharmacology.
[2] A. Alunno,et al. Pathogenesis of rheumatoid arthritis: one year in review 2022. , 2022, Clinical and experimental rheumatology.
[3] F. Cacciapaglia,et al. Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis , 2022, Journal of personalized medicine.
[4] Y. Lee,et al. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis , 2022, Zeitschrift für Rheumatologie.
[5] M. Dougados,et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis , 2021, Annals of the Rheumatic Diseases.
[6] Y. Lee,et al. Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. , 2021, International journal of clinical pharmacology and therapeutics.
[7] Y. Lee,et al. Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis , 2021, Zeitschrift für Rheumatologie.
[8] Mengsi Liu,et al. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis , 2021, Frontiers in Immunology.
[9] A. Blauvelt,et al. Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS) , 2021, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[10] R. Caporali,et al. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis , 2020, Expert review of clinical immunology.
[11] T. Huizinga,et al. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity , 2020, Rheumatology and Therapy.
[12] M. Dougados,et al. EULAR definition of difficult-to-treat rheumatoid arthritis , 2020, Annals of the Rheumatic Diseases.
[13] Tsutomu Takeuchi,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.
[14] K. Kawakami,et al. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects , 2019, BMC Pharmacology and Toxicology.
[15] M. Genovese,et al. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension , 2019, Arthritis Research & Therapy.
[16] C. Codreanu,et al. Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort. , 2019, Biologicals : journal of the International Association of Biological Standardization.
[17] P. Vlachos,et al. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis , 2019, Clinical Rheumatology.
[18] Bernice G Gershenson,et al. Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry , 2019, The Journal of Rheumatology.
[19] Donghoon Shin,et al. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects , 2018, Drug design, development and therapy.
[20] J. Frampton. SB5: An Adalimumab Biosimilar , 2018, BioDrugs.
[21] R. Moots,et al. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis , 2018, Current Rheumatology Reports.
[22] O. Hainzl,et al. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications , 2018, Expert opinion on biological therapy.
[23] A. Messori,et al. Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis. , 2018, Clinical and experimental rheumatology.
[24] S. Bae,et al. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials , 2018, Clinical Rheumatology.
[25] M. Weinblatt,et al. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis , 2017, Arthritis & rheumatology.
[26] A. Niewiarowski,et al. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects , 2017, British journal of clinical pharmacology.
[27] P. Vlachos,et al. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects , 2016, British journal of clinical pharmacology.
[28] Juliana de Oliveira Costa,et al. Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials. , 2013, Revista brasileira de reumatologia.
[29] G. Burmester,et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease , 2012, Annals of the rheumatic diseases.
[30] David T Felson,et al. UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .
[31] A. Silman,et al. UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .
[32] A. Silman,et al. Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .
[33] R. Pontarolo,et al. A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis , 2010, Rheumatology International.
[34] R. Pontarolo,et al. Meta‐analysis of the Efficacy and Safety of Adalimumab, Etanercept, and Infliximab for the Treatment of Rheumatoid Arthritis , 2010, Pharmacotherapy.
[35] P. V. van Riel,et al. The Disease Activity Score and the EULAR response criteria. , 2005, Clinical and experimental rheumatology.
[36] M. Uffmann,et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score , 2005, Arthritis research & therapy.
[37] V. Strand,et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). , 2003, The Journal of rheumatology.
[38] P. Tugwell,et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.
[39] M. Prevoo,et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.